Alisertib
Small Cell Prostate Cancer
Weill Medical College of Cornell UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the Small Cell Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin M.D. Anderson Cancer Center | Phase 2 | BB |
Pembrolizumab Rahul Aggarwal | Phase 2 | B |
PREDNISONE TABLETS Fred Hutchinson Cancer Center | Phase 2 | B |
CABAZITAXEL M.D. Anderson Cancer Center | Phase 2 | B |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | CCC |
View all 22 →
Same molecule, other indications
Alisertib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →